title: [Response criteria for malignant melanoma: RECIST and irRC].
abstract: In the field of oncology the response evaluation criteria in solid tumors (RECIST) currently represent the most commonly used and validated radiological response criteria for objective treatment monitoring of conventional chemotherapy. For therapy monitoring of classical cytostatic and cytotoxic tumor therapies RECIST has been tested and successfully validated in many clinical studies. However, with the introduction of novel molecular drugs limitations of these size-based criteria became obvious due to response patterns which are not reflected by RECIST. Thus, for a comprehensive evaluation of modern immunotherapeutic agents new immune-related response criteria (irRC) were developed.This review gives a brief overview of the most important radiological response criteria RECIST 1.0 and 1.1 as well as irRC for malignant melanoma.
authors: Institut für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Köln, Kerpener Str. 62, 50937, Köln, Deutschland.
authors: J
authors: J
authors: Spiro
authors: D
authors: D
authors: Maintz
authors: T
authors: T
authors: Persigehl
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003952:Diagnostic Imaging / Q000592:standards*; D016903:Drug Monitoring / Q000592:standards*; D006801:Humans; D007167:Immunotherapy / Q000592:standards; D008545:Melanoma / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary*; D066066:Response Evaluation Criteria in Solid Tumors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
references: J Dtsch Dermatol Ges. 2013 Aug;11 Suppl 6:1-116, 1-126
references: 24028775
references: J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16
references: 10655437
references: Clin Cancer Res. 2013 Jul 15;19(14 ):3936-43
references: 23743568
references: Clin Cancer Res. 2009 Dec 1;15(23 ):7412-20
references: 19934295
references: Rofo. 2014 May;186(5):466-73
references: 24563412
references: Eur J Cancer. 2009 Jan;45(2):261-7
references: 19091550
references: Eur J Cancer. 2009 Jan;45(2):228-47
references: 19097774
references: J Immunother Cancer. 2014 Nov 18;2(1):40
references: 25411640